Prezista (Darunavir) Patent Expiration, LOE Window & CMS Spending

Prezista (Darunavir) by Johnson & Johnson: FDA Orange Book core substance LOE 2027-06-26, 10 AB generics, $44.4M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN021976 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-06-26
Last Listed Patent or Exclusivity Date2027-06-26
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$44.4M
2024 Medicare Part D Spend$24.7M
2024 Medicaid Spend$19.6M
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 18.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.